A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Active:	No
Cancer Type:	Bile Duct Cancer Gynecologic Cancers Ovarian Cancer Prostate Cancer	NCT ID:	NCT04972981
Trial Phases:	Phase I	Protocol IDs:	ADCT-901-101 (primary) NCI-2021-10797 2021-002292-19
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	ADC Therapeutics S.A.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04972981

Summary

The primary objectives of this study are to identify the recommended phase 2 dose (RP2D)
and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of
ADCT-901.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.